Central Lab Market Size & Share 2026-2035

Central Lab Market Size

The global central lab market was estimated at USD 4.1 billion in 2025. The market is expected to grow from USD 4.4 billion in 2026 to USD 7.4 billion in 2035, at a CAGR of 6.1% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is driven by several factors, including the growth in global clinical trials, technological advancements in testing equipment, extensive growth in research and development investments, and increasing outsourcing by hospitals and clinics, among other factors.

Rising test volumes due to growing disease burden, improved logistics and sample transportation networks, and growth of genomic and molecular testing are expected to fuel the industry's growth. LabCorp, IQVIA Laboratories, Eurofins Scientific, Thermo Fisher Scientific, and Quest Diagnostics are among the leading players operating in the market. These players mainly focus on geographic expansion, integration of advanced technologies, partnership with pharma and biotech companies, strong R&D, and collaboration with local or regional healthcare providers, among other factors.

The market has increased from USD 3.5 billion in 2022 and reached USD 3.9 billion in 2024, with a historic growth rate of 5.6%. A significant factor affecting the overall growth of the central laboratory business is the increasing number of clinical studies with multiple site locations, which need to use a common protocol for standardized methodology, consistent testing results, and compliance with applicable regulatory requirements across countries. For instance, according to a recently published article in Invest India, over 18,000 new clinical trials were registered in India in 2024 alone, which is 50% more compared to the previous year. The centralized clinical laboratory service also supports global logistical coordination, provides standard testing supplies (e.g., kits), can track the movement of specimens from collection sites through the entire supply chain, and reports the final test results in a standard format.

Additionally, as emerging markets become more of an important source of patients and as decentralized clinical trial methodologies become more prevalent, the requirement for reliable infrastructure to provide central laboratory services may continue to increase, thereby reinforcing central laboratories' pivotal role in global clinical development.

Further, there has been ongoing innovation in testing equipment that has significantly enhanced the capacity and efficiency of central laboratories to perform tests. High-throughput analyzers, automation systems, advanced molecular technologies, and digital pathology systems provide laboratories the ability to analyze large volumes of samples with higher levels of accuracy and reproducibility than before. Upgrading existing laboratory equipment to a more efficient system allows for a consistent level of testing across multiple study locations, thus improving the integrity of the data generated by central laboratories. Furthermore, given the increasing complexity and volume of data generated by clinical trials, continued technological advances in testing are positioning central laboratories as critical partners in creating high-quality and reliable clinical data.

A central lab is a dedicated facility or group of laboratories that provides comprehensive laboratory testing services for clinical trials, pharmaceutical research, and various diagnostic purposes. These labs are equipped with advanced technologies and staffed by skilled professionals to conduct a wide range of tests and analyses on biological samples, including blood, urine, tissue, and other specimens.

Central Lab Market Trends

Growth of precision medicine and biomarker testing, expansion of global and decentralized clinical trials, automation and digital transformation, and emphasis on data quality and regulatory compliance are among the key trends shaping the market growth trajectory.

• There is a growing demand for advanced biomarkers, genomic, and companion diagnostic testing because of the shift towards precision medicine in healthcare. Central labs are important in providing specialized assays, validated methodologies, and consistent data generation that are needed to support targeted therapy.
• Additionally, the move towards globalization of the clinical trials has created a need for central labs to have adequate logistics, harmonized protocols, and established laboratory networks to facilitate the efficient handling of samples while preserving the quality of the data obtained from participating patients regardless of their geography.
• Further, the growing usage of laboratory automation, robotics, and laboratory information systems is enhancing throughput, accuracy, and turnaround times. Digital platforms also provide the means for improved real-time data visibility, regulatory compliance, and integration with clinical trial management systems.
• Moreover, as regulatory requirements become stricter and due to the growing data complexity, sponsors are moving to central laboratories with strong quality systems, standardized processes, and sophisticated data governance to produce reliable results and smooth regulatory submissions.

Central Lab Market Analysis

Based on services, the central lab market is segmented into biomarker services, anatomic pathology/histology, microbiology services, specimen management & storage, genetic services, and other services. The biomarker services segment accounted for a majority share of 31.3% in 2025. Increasing outsourcing by hospitals and clinics is anticipated to fuel the segmental growth. The segment is expected to reach USD 2.6 billion by 2035, growing at a CAGR of 7.2% during the forecast period.

• Biomarker services fall into the core segments of the central laboratory market as they are essential for both the discovery of new medicines through drug development and precision medicine.
• Additionally, biomarker services assist in patient stratification, verifying treatment targets, monitoring safety, and determining how well patients are responding to various treatments in all phases of clinical trials. Growing use of molecular, genetic, and protein-based biomarkers has created an increased demand for standardized high-sensitivity testing.
• Further, central laboratories offer the validated assays, consistent methodology, and ability to manage large volumes of data needed to conduct biomarker-based trials.
• The anatomic pathology/histology segment is anticipated to reach around USD 1.8 billion by 2035. Histopathology and anatomical pathology are crucial components of the diagnosis for disease conditions, including the staging and evaluation of treatment in the case of tissue specimens.
• In addition, central laboratories provide a standardized method for the processing, staining, imaging, and interpretation of tissues in various studies from multiple investigation sites. The rising use of biopsy-based endpoints in clinical trials and the use of digital pathology solutions in clinical trials are placing an increased demand on the need for centralized expertise in these areas.
• Moreover, these services ensure that the entire process, from preparing the slides consistently to having excellent imaging and conducting expert pathology reviews, is performed to reduce variances in the preparation and interpretation of slides across different sites.
• The microbiology services segment was valued at USD 789.3 million in 2025. The evaluation and support of infectious diseases through lab testing are important parts of microbiology services.
• Moreover, with the growing focus on infectious disease research, vaccine development, and immunology testing, there is an increasing need for centralized microbiological testing. Microbiology testing is also used to support contamination control and biosafety.

Based on application, the central lab market is categorized into oncology, neurology, cardiology, infectious diseases, and other applications. The oncology segment generated the highest revenue of USD 1.3 billion in 2025.

• Oncology represents the largest and most complex application area for central laboratory services. This is because cancer clinical trials require many different types of biomarker assays (genomic profiling, histopathology, etc.), which can be done easily through central laboratories, as they enable standardized testing among different trial locations to provide accuracy in both patient selection as well as in evaluating a trial's response to treatment.
• Further, the growing number of targeted therapies, immunotherapies, and cell-based therapies adds to the need for advanced laboratory capabilities.
• Centralized oncology testing improves data consistency, supports adaptive trial designs, and develops a comprehensive set of biomarker-driven insights, making central laboratories a critical component to the success of advanced cancer research and development.
• The neurology segment was valued at USD 1.1 billion in 2025. The use of central laboratory services for biomarker testing, biofluid analysis, and monitoring the progression of diseases such as neurodegenerative disorders is becoming a standard part of neurological research in many cases.
• Sensitive and reproducible assays are needed to detect small biological changes occurring over the course of time. Furthermore, the expansion of clinical trials studying Alzheimer’s disease and other rare neurological disorders creates a need for centralized laboratory support. This helps to minimize the potential variability and thereby increases the reliability of trial results while simultaneously enhancing regulatory confidence in the data generated from the trial.
• The cardiology segment was valued at USD 764.3 million in 2025. Cardiology applications drive demand for centralized testing of cardiac biomarkers, coagulation parameters, and metabolic indicators.
• Additionally, there has been an increase in the demand for central laboratories to provide standardized testing methods for high-sensitivity assays used to determine cardiovascular risk, evaluate drug safety, and support therapeutic efficacy.
• Large patient populations and the nature of multi-site trial designs make central laboratories particularly useful in cardiology studies where there is a high volume of sample collection and analysis; thus, they can provide high turnaround times, consistent methodology, and comprehensive data integration.

Based on end use, the central lab industry is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and other end-users. The pharmaceutical and biotechnology companies segment accounted for the leading market share of 45.6% in 2025.

• Pharmaceutical and biotechnology companies dominate the central lab market due to their substantial investment in R&D, clinical trials, and clinical laboratory services, which require extensive testing, biomarker analyses, and validation services. The need for accurate, high-quality results in drug development drives their significant reliance on central labs.
• In addition, many companies outsource their testing needs to a central laboratory in order to reduce their infrastructure costs and access the unique assays provided by the central laboratory.
• Central laboratories provide scalable, globally located, standardized workflows that are critical to executing complex clinical programs.
• Further, their extensive R&D and clinical trial needs, which require specialized, regulated testing services to ensure compliance and accuracy, contribute to their segmental growth.
• The academic and research institutes segment was valued at USD 1.3 billion in 2025. Research and academic institutions use a central laboratory service in order to support investigator-driven research, translational studies, and collaborative clinical trials.
• Furthermore, central laboratories provide researchers with access to sophisticated testing technologies, standardized testing methods, and the ability to interpret tests by professionals who might not be available in-house. The use of these central laboratory resources enhances the quality of research data, promotes the development of multi-center collaborations, and increases the reproducibility of research results.

 North America Central Lab Market

The North America market accounted for majority share of 36.8% in 2025 and is anticipated to show notable growth over the forecast period.

• The U.S. market was valued at USD 1.4 billion in 2025, up from USD 1.3 billion in 2024. Rising test volumes due to growing disease burden and automation to improve efficiency and margins are among the key factors supporting the industry growth.
• The increasing focus on personalized medicine in North America is boosting demand for advanced diagnostic services and biomarkers, hence driving the demand for central labs in the region.
• Additionally, the U.S. government and private sector are investing heavily in biomedical research and clinical trials, leading to higher demand for central lab services to support these initiatives, thereby driving the market growth.
• Further, the rising incidence of chronic diseases such as cancer and diabetes necessitates more comprehensive testing and research, thus fueling the growth of central labs in North America.

Europe Central Lab Market

Europe accounted for a substantial share of the global market and was valued at USD 1.2 billion in 2025.

• The central laboratory market in Europe is growing steadily due to a strong clinical research ecosystem, well-established regulatory frameworks, and increasing complexity of clinical trials.
• Pharmaceutical and biotechnology firms throughout Western and Northern Europe are turning to centralizing testing in order to ensure the consistency of data and to meet all regulations across multicountry clinical trial studies.
• Furthermore, growth is also being supported through increased biomarker-driven clinical trials, clinical research in the area of precision oncology, and newer technology regarding pathology.

Asia Pacific Central Lab Market

The Asia Pacific market accounted for a substantial share of the market and was valued at USD 1 billion in 2025.

• The Asia Pacific continues to be a fast-growing region globally in the central laboratory market. Growth continues to be driven primarily by the increase in clinical trial activity across all application sectors.
• There are many cost benefits associated with conducting clinical trials in this region along with the rapid growth of the biopharmaceutical industry in Asia Pacific. Countries such as China, India, Japan, and South Korea have become key clinical study locations globally and regionally.
• In addition, both local pharmaceutical and biotechnology companies in this region are beginning to create a pipeline of new product research, which may stimulate demand for biomarker and molecular testing. Governments throughout the Asia Pacific region also continue to implement stronger regulations for clinical research and laboratory operations, creating an opportunity for sponsors to begin working with qualified central laboratories.
• Moreover, increased regional laboratory networks and logistics will continue to support the expanding market growth over the analysis timeframe.

Latin America Central Lab Market

The Latin American market is anticipated to exhibit remarkable growth during the analysis period.

• The central laboratory market in Latin America is continuing to grow as the region has become appealing to many sponsors of clinical trials and research due to its diverse patient population and improving clinical research infrastructure. For example, Brazil, Mexico, and Argentina have attracted increasing amounts of investment for clinical research, particularly in the fields of oncology and infectious disease.

• Additionally, central laboratories play a key role by providing sample logistics management (tracking, handling, and shipping of specimens), standardization of testing methods, and having a system in place for maintaining data quality at all clinical trial sites in geographically dispersed areas.
• Further, the Central Laboratory Market is heavily supported through increased collaboration between global sponsors of clinical research (e.g., specialty drug companies) and local/regional research organizations conducting the trials.

Middle East and Africa Central Lab Market

The Middle East and Africa market is expected to experience substantial growth over the analysis timeframe.

• The MEA Central Laboratories market has been growing at a steady pace, primarily due to an increase in healthcare expenditure, greater emphasis on clinical research, and a trend towards upgrading and centralizing the delivery of advanced diagnostics.
• In addition, there is a particular focus on building the required infrastructure for conducting research in the Gulf States and attracting global clinical trial organizations to those countries. The result of these efforts is a strong demand for centralized laboratory services from the Gulf's health care providers.
• Further, the use of a central laboratory can assist in overcoming fragmentation of local testing capabilities since it can provide uniform methodologies and reliable data.

Central Lab Market Share

The centralized laboratory market has a moderate level of concentration among providers. It includes a combination of various large global providers and a number of smaller regional (or specialty) laboratories. Major players have extensive multi-regional laboratory networks where they perform clinical trial testing and large-volume diagnostics using standardized methods, high-volume automated processes, and integrated data management systems. These players can carry out large, complex, multicenter clinical studies, provide regulatory compliance in many countries, and ensure timely delivery of the results.

Additionally, apart from the price, service breadth and technology may become the differentiating elements of competition. Companies may use advanced biomarker analyses, molecular and genomic tests, companion diagnostics, and comprehensive sample logistics (e.g., global management of kits and cold chain delivery) to distinguish themselves from each other. The development of digital platforms, laboratory information systems, and analysis of data will enhance sponsors' visibility, ensure data integrity, and improve sponsors' oversight of the trial in real time.

Further, mid-sized and specialty companies continue to invest in strategic partnerships that allow them to better connect with their customers while expanding their capabilities without the need for large capital investments or extensive facilities.

Moreover, companies that previously competed with each other are now engaging in a collaborative business model, utilizing technology to integrate their services, reducing administrative costs, and expand testing offerings. Mergers, partnerships, and increased capacities are examples of how these competitors are evolving to provide better, more efficient services and products while supporting the increased diversity and complexity associated with clinical research and precision medicine programs.

Central Lab Market Companies

A few of the prominent players operating in the global central lab industry include:

• ACM Global Laboratories
• BioAgilytix Labs
• Cerba Research
• Eurofins Scientific
• Frontage Laboratories
• ICON plc
• IQVIA Laboratories
• LabConnect
• Labcorp
• Lambda Therapeutic Research
• Medicover Integrated Clinical Services (MICS)
• Medpace, Inc.
• Parexel International Corporation
• Quest Diagnostics
• Thermo Fisher Scientific
• Versiti

 

• LabCorp

Focuses on expanding central lab and esoteric testing capabilities, leveraging automation, digital reporting, and global logistics to support complex clinical trials and integrated diagnostics solutions.

• Thermo Fisher Scientific

Leverages integrated instruments, consumables, and central lab services, focusing on high-value specialty testing, companion diagnostics, and strategic partnerships with pharmaceutical and biotechnology sponsors.

• Quest Diagnostics

Strengthens its position through scale-driven efficiencies, automation, and advanced data connectivity, while expanding specialized testing and central lab services for pharmaceutical research and large health systems.

Central Lab Industry News

• In February 2026, ARUP Laboratories, a leading nonprofit reference laboratory in the U.S., announced the launch of a new Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners. This development will serve as an ecosystem for validating technologies and accelerating next-generation diagnostics from concept to commercialization.
• In May 2025, Teddy Laboratory, a subsidiary of Tigermed, signed a strategic cooperation agreement with LabConnect, a leading player in global central laboratory services. Under this agreement, the two entities will jointly build a full-chain laboratory service system covering both China and international markets to accelerate the development and commercialization of innovative drugs worldwide. Under this development, Teddy Laboratory will become LabConnect's preferred laboratory partner in China for different lab services.
• In September 2023, Cerba HealthCare announced the acquisition of CIRION BIOPHARMA RESEARCH INC. (CIRION), recognized for its integrated bioanalytical and global central laboratory services. This acquisition expanded the company’s service portfolio and enabled it to increase its customer base.

The global central lab market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Services

• Biomarker services
• Anatomic pathology/histology
• Microbiology services
• Specimen management & storage
• Genetic services
• Other services

Market, By Application

• Oncology
• Neurology
• Cardiology
• Infectious diseases
• Other applications

Market, By End Use

• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE